北美抗体药物偶联物市场预测至 2030 年 - 区域分析 - 按技术（可裂解接头和不可裂解接头）、应用（血液癌、乳腺癌、卵巢癌、尿路上皮癌等）和分销渠道（医院药房、零售药店和网上药店）
FDA 对 ADC 的批准增加推动了北美抗体药物偶联物市场
根据一篇文章《An Insight into FDA》 2021 年 9 月在美国国家医学图书馆发布的《批准用于癌症治疗的抗体药物偶联物》中，2017 年批准了 8 个 ADC，2021 年 9 月增加到 11 个。FDA 还批准了更多 ADC，包括 Lumoxiti、到2022年11月底。全球有超过50家生物制药公司参与开发ADC。这些公司主要针对血癌和其他癌症类型，如肺癌、膀胱癌和妇科肿瘤。此外，2021年6月，美国投资银行Evercore和Evercore ISI预计，到2030年，两家公司每年的ADC销售额将超过200亿美元。 ADC 的批准和商业化不断增加，导致市场显着增长。以下是 FDA 批准的 ADC 列表。
表 1. FDA 批准的 ADC 列表
Sr.编号 公司商品名称 ADC 药物癌症类型批准年份
1 辉瑞/惠氏 Mylotarg Gemtuzumab ozogamicin 复发性急性髓性白血病 (AML) 2000； 2017
2 Seagen Genetics、Millennium/Takeda Adcetris Brentuximab vedotin 复发性 HL 和复发 sALCL 2011
3 Genentech、罗氏 Kadcyla Trastuzumab emtansine HER2 阳性转移性乳腺癌 (mBC) 2013
< br>4 辉瑞/惠氏 Besponsa Inotuzumab ozogamicin 复发或难治性 CD22 阳性 B 细胞前体急性淋巴细胞白血病 2017
5 阿斯利康 Lumoxiti Moxetumomab pasudotox 成人复发或难治性毛细胞白血病 (HCL) 2018
< br>6 Genentech、Roche Polivy Polatuzumab vedotin-piiq 复发或难治性弥漫性大 B 细胞淋巴瘤 (DLBCL) 2019
7 Astellas/Seagen Genetics Padcev Enfortumab vedotin 接受 PD-1 治疗的成人转移性尿路上皮癌或 PD-L1 抑制剂，以及含 Pt 疗法 2019
8 阿斯利康/第一三共 Enhertu 曲妥珠单抗 deruxtecan 成人转移性 HER2 阳性乳腺癌，接受过两种或两种以上基于抗 HER2 的治疗方案 2019
9 免疫医学 Trodelvy Sacituzumab govitecan 成人转移性三阴性乳腺癌 (mTNBC)，以及复发或难治性转移性疾病患者接受过至少两种既往治疗的患者 2020
10 葛兰素史克 (GSK) Blenrep Belantamab mafodotin -blmf 2020 年成人复发或难治性多发性骨髓瘤，于 2022 年 11 月 22 日在美国撤回。
11 ADC 疗法 Zynlonta Loncastuximab tesirine-lpyl 大 B 细胞淋巴瘤 2021
12 Seagen Inc Tivdak Tisotumab vedotin-tftv 复发性或转移性宫颈癌 2021
13 ImmunoGen Elahere Mirvetuximab soravtansine 铂耐药性卵巢癌 2022
北美抗体药物偶联物市场概述
北美抗体药物偶联物 (ADC) 市场根据美国、加拿大和墨西哥进行分析。该地区的市场增长归因于 ADC 研发的增加、产品批准的增加、对 ADC 认识的提高以及运营商之间合并、合作和伙伴关系数量的增加。此外，癌症发病率的显着上升是导致 ADC 需求增加的其他主要因素之一。
此外，公司之间不断加强合作伙伴关系以在不同地区扩展其技术，从而促进市场增长。 2023 年 8 月，ImmunoGen, Inc. 和武田制药有限公司在日本合作开发和商业化 ELAHERE（免疫原 ADC 疗法）。根据合作协议，ImmunoGen, Inc. 在获得 FDA 加速批准 ELAHERE 用于治疗铂类耐药卵巢癌后将获得预付款和额外付款。如果武田通过 ELAHERE 在日本的净销售额实现某些监管和商业里程碑以及两位数的特许权使用费，它将向ImmunoGen, Inc.支付额外款项。不过，Immunogen 保留其独家生产权，并将供应该产品进行开发和销售。在日本商业化。作为回报，武田将负责所有监管备案，并拥有在日本开发和商业化 ELAHERE 的独家许可。
北美抗体药物偶联物市场收入和预测到 2030 年（百万美元）
北美抗体药物偶联物市场细分
北美抗体药物偶联物市场已细分基于技术、应用、分销渠道和国家。
根据技术，北美抗体药物偶联物市场抗体药物偶联物市场分为可裂解接头和不可裂解接头。到2022年，可裂解接头部分将占据更大的份额。
根据应用，北美抗体药物偶联物市场抗体药物偶联物市场分为血癌、乳腺癌、卵巢癌、尿路上皮癌等。乳腺癌细分市场在 2022 年占据最大份额。
根据分销渠道，北美抗体药物偶联物市场抗体药物偶联物市场分为医院药房、零售药房和在线药房。 2022 年，医院药房市场占据最大份额。
按国家/地区划分，北美抗体药物偶联物市场分为美国、加拿大和墨西哥。 2022 年，美国将主导北美抗体药物偶联物市场。
ADC Therapeutics SA、辉瑞公司、罗氏公司、ImmunoGen, Inc、葛兰素史克公司、吉利德科学公司、阿斯利康公司、安斯泰来制药公司、 RemeGen Co Ltd 和 Takeda Pharmaceutical Co Ltd 是北美抗体药物偶联物市场的一些领先公司。
Table of Content
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Antibody Drug Conjugates Market - Key Industry Dynamics
4.1 Key Market Drivers:
4.1.1 Growing Strategic Partnerships to Develop Antibody Drug Conjugates
4.1.2 Rising Incidences of Cancer Cases
4.1.3 Increasing FDA Approvals for ADCs
4.2 Market Restraints
4.2.1 High Cost of ADCs Development and Commercialization
4.3 Market Opportunities
4.3.1 Increasing Investments to Develop ADCs
4.4 Market Trends
4.4.1 Escalating Pipeline of ADCs
4.5 Impact Analysis:
5. Antibody Drug Conjugates Market - North America Market Analysis
5.1 North America Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030
6. North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Technology
6.1 Overview
6.2 North America Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
6.3 Cleavable Linker
6.3.1 Overview
6.3.2 Cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Non-cleavable Linker
6.4.1 Overview
6.4.2 Non-cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7. North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Application
7.1 Overview
7.2 North America Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
7.3 Blood Cancer
7.3.1 Overview
7.3.2 Blood Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Breast Cancer
7.4.1 Overview
7.4.2 Breast Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Ovarian Cancer
7.5.1 Overview
7.5.2 Ovarian Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Urothelial Cancer
7.6.1 Overview
7.6.2 Urothelial Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
8. North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Distribution Channel
8.1 Overview
8.2 North America Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacies
8.4.1 Overview
8.4.2 Retail Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
9. North America Antibody Drug Conjugates Market - Country Analysis
9.1 North America Antibody Drug Conjugates Market, Revenue and Forecast To 2030
9.1.1 Overview
9.1.2 North America Antibody Drug Conjugates Market Breakdown, by Country Revenue (2022) (US$ Million)
9.1.3 North America: Antibody Drug Conjugates Market, by Countries,2022 and 2030 (%)
9.1.3.1 US
9.1.3.1.1 Overview
9.1.3.1.2 US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.1.3 US: Antibody Drug Conjugates Market, by Technology
9.1.3.1.4 US: Antibody Drug Conjugates Market, by Application
9.1.3.1.5 US: Antibody Drug Conjugates Market, by Distribution Channel
9.1.3.2 Canada
9.1.3.2.1 Overview
9.1.3.2.2 Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.2.3 Canada: Antibody Drug Conjugates Market, by Technology
9.1.3.2.4 Canada: Antibody Drug Conjugates Market, by Application
9.1.3.2.5 Canada: Antibody Drug Conjugates Market, by Distribution Channel
9.1.3.3 Mexico
9.1.3.3.1 Overview
9.1.3.3.2 Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.3.3 Mexico: Antibody Drug Conjugates Market, by Technology
9.1.3.3.4 Mexico: Antibody Drug Conjugates Market, by Application
9.1.3.3.5 Mexico: Antibody Drug Conjugates Market, by Distribution Channel
10. Antibody Drug Conjugates Market-Industry Landscape
10.1 Overview
10.2 Organic Growth Strategies
10.2.1 Overview
10.3 Inorganic Growth Strategies
10.3.1 Overview
10.4 Companies' Manufacturing Capacities and Capabilities
11. Company Profiles
11.1 ADC Therapeutics SA
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Pfizer Inc
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Hoffmann-La Roche Ltd
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 ImmunoGen, Inc.
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 GSK Plc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Gilead Sciences Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 AstraZeneca Plc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Astellas Pharma Inc
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 RemeGen Co Ltd
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 Takeda Pharmaceutical Co Ltd
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms
List of Tables
Table 1. North America Antibody Drug Conjugates Market Segmentation
Table 2. New Cancer Cases Worldwide, in 2020
Table 3. List of FDA-Approved ADCs
Table 4. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 5. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 6. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 7. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 8. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 9. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 10. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 11. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 12. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 13. Recent Organic Growth Strategies in Antibody Drug Conjugates Market
Table 14. Recent Inorganic Growth Strategies in the Antibody Drug Conjugates Market
Table 15. Glossary of Terms, Antibody Drug Conjugates Market
List of Figures
Figure 1. North America Antibody Drug Conjugates Market Segmentation, By Country
Figure 2. Key Insights
Figure 3. North America Antibody Drug Conjugates Market - Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. North America Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030
Figure 6. North America Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
Figure 7. Cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Non-Cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. North America Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
Figure 10. Blood Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Breast Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Ovarian Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Urothelial Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Others: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. North America Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 16. Hospital Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Retail Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Online Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. North America Antibody Drug Conjugates, by Key Country - Revenue (2022) (US$ Million)
Figure 20. North America: Antibody Drug Conjugates Market, By Key Countries, 2022 and 2030 (%)
Figure 21. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
1. ADC Therapeutics SA
2. Pfizer Inc
3. Hoffmann-La Roche Ltd
4. ImmunoGen Inc
5. GSK Plc
6. Gilead Sciences Inc
7. AstraZeneca Plc
8. Astellas Pharma Inc
9. RemeGen Co Ltd
10. Takeda Pharmaceutical Co Ltd
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America antibody drug conjugates market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in North America antibody drug conjugates market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution